Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.
To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.
Please help improve GET-Evidence by evaluating evidence for this variant!
You are viewing an old version of this page that was saved on May 17, 2010 at 6:21pm by PharmGKB Importing Robot.
Insufficiently evaluated not reviewed
(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)
Summary of published research, and additional commentary
Added in this revision:
Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ,
Dahut WL, Miao X, Figg WD. A pharmacogenetic study of docetaxel and thalidomide
in patients with castration-resistant prostate cancer using the DMET genotyping
platform. Pharmacogenomics J. 2009 Dec 29. [Epub ahead of print] PubMed PMID: